Pharmacy Led Reviews of Anti-Psychotic Prescribing for People with Dementia (BMC Psychiatry)

[A brief reference to this item appears in: Dementia and Elderly Care: the Latest Evidence Newsletter (RWHT), Volume 3 Issue 3, October 2012].


Antipsychotics prescribed for people with dementia are associated with approximately 1800 excess deaths in the UK annually. Reducing the prescribing of antipsychotics is a public health priority.

A project conducted at Medway Primary Care Trust (PCT) in the UK involved the dementia register being searched by a pharmacy technician to identify people with dementia prescribed antipsychotics, and then a trained specialist pharmacist performing targeted clinical medication reviews for these people where appropriate. Data from 59 practices showed 15.3% of 1051 people on the dementia register were receiving low-dose antipsychotics. People with dementia living in residential homes were 3.5 times more likely to receive an antipsychotic (25.5% of care home residents (118/462) compared with 7.3% of people living at home (43/589)). Of the 161 people with dementia prescribed low-dose antipsychotics, 91 were receiving on-going treatment from local secondary care mental health services or Learning Disability Teams. The remaining 70 patients had the antipsychotic withdrawn or the dosage reduced following the pharmacy-led medication review.

Overall 15.3% of people on the dementia register received a low-dose antipsychotics, and this may under-estimate the actual usage of antipsychotics in people with dementia. Antipsychotics are used more in care home settings. Pharmacist-led medication reviews can help to limit the prescribing of antipsychotics to people with dementia.

Full Text Link


Child, A. Clarke, A.  [and] Fox, C. [et al] (2012). A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry, September 25th 2012, Vol.12(1), 155. (Click here to view the PubMed abstract).

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in Antipsychotics, Community Care, For Doctors (mostly), For Researchers (mostly), For Social Workers (mostly), Management of Condition, NHS, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.